A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
1. Non-small cell lung cancer diagnosed initially through pathological histology.
2. There are 3-6 metastatic lesions.
3. No brain metastasis or the lesions are stable.
4. Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET genes. Note: The above English terms are all gene names).
5. ECOG (Eastern Cooperative Oncology Group) score: 0-1 point, with an expected, survival period of more than 3 months.
6. Aged between 18 and 75 years old.
7. Evaluated by PET-CT (including FDG and FMISO, not mandatory).
8. No contraindications for immunotherapy and radiotherapy.
9. The informed consent form has been signed.
You may not be if
1. Those with severe dysfunction of vital organs (heart, liver, kidney).
2. Those accompanied by other malignant tumors.
3. Those with uncontrolled heart diseases or having experienced a myocardial infarction within the past six months.
4. Those with a history of mental illness.
5. And other situations in which the researchers deem it inappropriate for the subjects to participate in the study.
Clareo Health | A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
